Biologic drugs in adult onset Still’s disease: a systematic review and meta-analysis of observational studies

Expert Review of Clinical Immunology

Volumn 13, Issue 11, 2017, Pages 1089-1097

  Ruscitti, Piero ^a   Ursini, Francesco ^b   Cipriani, Paola ^a   De Sarro, Giovambattista ^b   Giacomelli, Roberto ^a  

^a UNIVERSITY OF L'AQUILA   (Italy)

^b UNIVERSITY MAGNA GRAECIA OF CATANZARO   (Italy)

Author keywords

Adult onset Still s disease; anakinra; biologic drugs; tocilizumab; tumor necrosis factor inhibitor

Indexed keywords

BIOLOGICAL PRODUCT; INTERLEUKIN 1; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; INTERLEUKIN 6; MONOCLONAL ANTIBODY; TOCILIZUMAB; TUMOR NECROSIS FACTOR;

ADULT ONSET STILL DISEASE; ARTICLE; COCHRANE LIBRARY; DRUG EFFICACY; HUMAN; MEDLINE; META ANALYSIS; OBSERVATIONAL STUDY; REMISSION; SYSTEMATIC REVIEW; TREATMENT RESPONSE; WEB OF SCIENCE; ADULT; ANTAGONISTS AND INHIBITORS; IMMUNOLOGY; TREATMENT OUTCOME;

ADULT; ANTIBODIES, MONOCLONAL, HUMANIZED; BIOLOGICAL PRODUCTS; HUMANS; INTERLEUKIN 1 RECEPTOR ANTAGONIST PROTEIN; INTERLEUKIN-1; INTERLEUKIN-6; STILL'S DISEASE, ADULT-ONSET; TREATMENT OUTCOME; TUMOR NECROSIS FACTOR-ALPHA;

EID: 85029796091     PISSN: 1744666X     EISSN: 17448409     Source Type: Journal    
DOI: 10.1080/1744666X.2017.1375853     Document Type: Article

References (63)

1. Gerfaud-Valentin M, Jamilloux Y, Iwaz J, et al. Adult-onset Still’s disease. Autoimmun Rev. 2014;13:708–722.
2. Rosário C, Zandman-Goddard G, Meyron-Holtz EG, et al. The hyperferritinemic syndrome: macrophage activation syndrome, Still’s disease, septic shock and catastrophic antiphospholipid syndrome. BMC Med. 2013;11:185.
3. Colafrancesco S, Priori R, Valesini G., Presentation and diagnosis of adult-onset Still’s disease: the implications of current and emerging markers in overcoming the diagnostic challenge. Expert Rev Clin Immunol. 2015;11:749–761.
4. Ruscitti P, Cipriani P, Ciccia F, et al. H-ferritin and CD68(+)/H-ferritin(+) monocytes/macrophages are increased in the skin of adult-onset Still’s disease patients and correlate with the multi-visceral involvement of the disease. Clin Exp Immunol. 2016;186:30–38.
5. Ruscitti P, Ciccia F, Cipriani P, et al. The CD68(+)/H-ferritin(+) cells colonize the lymph nodes of the patients with adult onset Still’s disease and are associated with increased extracellular level of H-ferritin in the same tissue: correlation with disease severity and implication for pathogenesis. Clin Exp Immunol. 2016;183:397–404.
6. Cush JJ, Medsger TA, Jr, Christy WC, et al. Adult-onset Still’s disease. Clinical course and outcome. Arthritis Rheum. 1987;30:186–194.
7. Ruscitti P, Cipriani P, Masedu F, et al. Adult-onset Still’s disease: evaluation of prognostic tools and validation of the systemic score by analysis of 100 cases from three centers. BMC Med. 2016;14:194.
8. Ruscitti P, Cipriani P, Ciccia F, et al. Prognostic factors of macrophage activation syndrome, at the time of diagnosis, in adult patients affected by autoimmune disease: analysis of 41 cases collected in 2 rheumatologic centers. Autoimmun Rev. 2017;16:16–21.
9. Ruscitti P, Cipriani P, Di Benedetto P, et al. Increased level of H-ferritin and its imbalance with L-ferritin, in bone marrow and liver of patients with adult onset Still’s disease, developing macrophage activation syndrome, correlate with the severity of the disease. Autoimmun Rev. 2015;14:429–437.
10. Jamilloux Y, Gerfaud-Valentin M, Henry T, et al. Treatment of adult-onset Still’s disease: a review. Ther Clin Risk Manag. 2014;11:33–43.
11. Yoo DH., Treatment of adult-onset still’s disease: up to date. Expert Rev Clin Immunol. 2017 Jun 5:1–18 [Epub ahead of print]. DOI:10.1080/1744666X.2017.1332994.
12. Cipriani P, Ruscitti P, Carubbi F, et al. Methotrexate: an old new drug in autoimmune disease. Expert Rev Clin Immunol. 2014;10:1519–1530.
13. Cipriani P, Ruscitti P, Carubbi F, et al. Methotrexate in rheumatoid arthritis: optimizing therapy among different formulations. Current and emerging paradigms. Clin Ther. 2014;36:427–435.
14. Hong D, Yang Z, Han S, et al. Interleukin 1 inhibition with anakinra in adult-onset Still disease: a meta-analysis of its efficacy and safety. Drug Des Devel Ther. 2014;8:2345–2357.
15. Maria AT, Le Quellec A, Jorgensen C, et al. Adult onset Still’s disease (AOSD) in the era of biologic therapies: dichotomous view for cytokine and clinical expressions. Autoimmun Rev. 2014;13:1149–1159.
16. Ortiz-Sanjuán F, Blanco R, Calvo-Rio V, et al. Efficacy of tocilizumab in conventional treatment-refractory adult-onset Still’s disease: multicenter retrospective open-label study of thirty-four patients. Arthritis Rheumatol. 2014;66:1659–1665.
17. Ortiz-Sanjuán F, Blanco R, Riancho-Zarrabeitia L, et al. Efficacy of Anakinra in refractory adult-onset Still’s disease: multicenter study of 41 patients and literature review. Medicine (Baltimore). 2015;94:e1554.
18. Thornton T. Clinical judgement, expertise and skilled coping. J Eval Clin Pract. 2010;16:284–291.
19. Kienle GS, Kiene H. Clinical judgement and the medical profession. J Eval Clin Pract. 2011;17:621–627.
20. Stroup DF, Berlin JA, Morton SC, et al. Meta-analysis of observational studies in epidemiology: a proposal for reporting. Meta-analysis Of Observational Studies in Epidemiology (MOOSE) group. JAMA. 2000;283:2008–2012.
21. Higgins JP, Thompson SG, Deeks JJ, et al. Measuring inconsistency in meta-analyses. BMJ. 2003;327:557–560.
22. Egger M, Davey Smith G, Schneider M, et al. Bias in meta-analysis detected by a simple, graphical test. BMJ. 1997;315:629–634.
23. Duval S, Tweedie R. Trim and fill: A simple funnel-plot-based method of testing and adjusting for publication bias in meta-analysis. Biometrics. 2000;56:455–463.
24. Bannai E, Yamashita H, Kaneko S, et al. Successful tocilizumab therapy in seven patients with refractory adult-onset Still’s disease. Mod Rheumatol. 2016;26:297–301.
25. Cavalli G, Franchini S, Aiello P, et al. Efficacy and safety of biological agents in adult-onset Still’s disease. Scand J Rheumatol. 2015;44:309–314.
26. Cipriani P, Ruscitti P, Carubbi F, et al. Tocilizumab for the treatment of adult-onset Still’s disease: results from a case series. Clin Rheumatol. 2014;33:49–55.
27. Dall’Ara F, Frassi M, Tincani A, et al. A retrospective study of patients with adult-onset Still’s disease: is pericarditis a possible predictor for biological disease-modifying anti-rheumatic drugs need? Clin Rheumatol. 2016;35:2117–2123.
28. Elkayam O, Jiries N, Dranitzki Z, et al. Tocilizumab in adult-onset Still’s disease: the Israeli experience. J Rheumatol. 2014;41:244–247.
29. Fautrel B, Sibilia J, Mariette X, et al. Club Rhumatismes et Inflammation. Tumour necrosis factor alpha blocking agents in refractory adult Still’s disease: an observational study of 20 cases. Ann Rheum Dis. 2005;64:262–266.
30. Gerfaud-Valentin M, Maucort-Boulch D, Hot A, et al. Adult-onset still disease: manifestations, treatment, outcome, and prognostic factors in 57 patients. Medicine (Baltimore). 2014;93:91–99.
31. Giampietro C, Ridene M, Lequerre T, et al. Anakinra in adult-onset Still’s disease: long-term treatment in patients resistant to conventional therapy. Arthritis Care Res (Hoboken). 2013;65:822–826.
32. Husni ME, Maier AL, Mease PJ, et al. Etanercept in the treatment of adult patients with Still’s disease. Arthritis Rheum. 2002;46:1171–1176.
33. Iliou C, Papagoras C, Tsifetaki N, et al. Adult-onset Still’s disease: clinical, serological and therapeutic considerations. Clin Exp Rheumatol. 2013;31:47–52.
34. Laskari K, Tzioufas AG, Moutsopoulos HM. Efficacy and long-term follow-up of IL-1R inhibitor anakinra in adults with Still’s disease: a case-series study. Arthritis Res Ther. 2011;13:R91.
35. Lequerré T, Quartier P, Rosellini D, et al. Interleukin-1 receptor antagonist (anakinra) treatment in patients with systemic-onset juvenile idiopathic arthritis or adult onset Still disease: preliminary experience in France. Ann Rheum Dis. 2008;67:302–308.
36. Puéchal X, DeBandt M, Berthelot JM, et al. Tocilizumab in refractory adult Still’s disease. Arthritis Care Res (Hoboken). 2011;63:155–159.
37. Rossi-Semerano L, Fautrel B, Wendling D, et al. Tolerance and efficacy of off-label anti-interleukin-1 treatments in France: a nationwide survey. Orphanet J Rare Dis. 2015 Feb 15;10:19.
38. Sfriso P, Priori R, Valesini G, et al. Adult-onset Still’s disease: an Italian multicentre retrospective observational study of manifestations and treatments in 245 patients. Clin Rheumatol. 2016;35:1683–1689.
39. Song ST, Kim JJ, Lee S, et al. Efficacy of tocilizumab therapy in Korean patients with adult-onset Still’s disease: a multicentre retrospective study of 22 cases. Clin Exp Rheumatol. 2016;34:S64–S71.
40. Suematsu R, Ohta A, Matsuura E, et al. Therapeutic response of patients with adult Still’s disease to biologic agents: multicenter results in Japan. Mod Rheumatol. 2012;22:712–719.
41. Vitale A, Insalaco A, Sfriso P, et al. A snapshot on the on-label and off-label use of the interleukin-1 inhibitors in Italy among rheumatologists and pediatric rheumatologists: a nationwide multi-center retrospective observational study. Front Pharmacol. 2016 Oct 24;7:380. eCollection 2016.
42. Nordström D, Knight A, Luukkainen R, et al. Beneficial effect of interleukin 1 inhibition with anakinra in adult-onset Still’s disease. An open, randomized, multicenter study. J Rheumatol. 2012;39:2008–2011.
43. Nishina N, Kaneko Y, Kameda H, et al. The effect of tocilizumab on preventing relapses in adult-onset Still’s disease: a retrospective, single-center study. Mod Rheumatol. 2015;25:401–404.
44. Castañeda S, Blanco R, González-Gay MA. Adult-onset Still’s disease: advances in the treatment. Best Pract Res Clin Rheumatol. 2016;30:222–238.
45. Kim H-A, Sung J-M, Suh C-H. Therapeutic responses and prognosis in adult-onset Still’s disease. Rheumatol Int. 2012;32:1291–1298.
46. Giacomelli R, Ruscitti P, Alvaro S, et al. IL-1β at the crossroad between rheumatoid arthritis and type 2 diabetes: may we kill two birds with one stone? Expert Rev Clin Immunol. 2016;12:849–855.
47. Guilpain P, Le Quellec A. About the complexity of adult onset Still’s disease… and advances still required for its management. BMC Med. 2017;15:5.
48. Giancane G, Minoia F, Davì S, et al. IL-1 inhibition in systemic juvenile idiopathic arthritis. Front Pharmacol. 2016;7:467.
49. Cimaz R. Systemic-onset juvenile idiopathic arthritis. Autoimmun Rev. 2016;15:931–934.
50. Quartier P, Allantaz F, Cimaz R, et al. A multicentre, randomised, double-blind, placebo-controlled trial with the interleukin-1 receptor antagonist anakinra in patients with systemic-onset juvenile idiopathic arthritis (ANAJIS trial). Ann Rheum Dis. 2011;70:747–754.
51. Kimura Y, Grevich S, Beukelman T, et al. Pilot study comparing the Childhood Arthritis & Rheumatology Research Alliance (CARRA) systemic juvenile idiopathic arthritis consensus treatment plans. Pediatr Rheumatol Online J. 2017;15:23.
52. Grom AA, Ilowite NT, Pascual V, et al. Rate and clinical presentation of macrophage activation syndrome in patients with systemic Juvenile idiopathic arthritis treated with canakinumab. Arthritis Rheumatol. 2016;68:218–228.
53. Ilowite NT, Prather K, Lokhnygina Y, et al. Randomized, double-blind, placebo-controlled trial of the efficacy and safety of rilonacept in the treatment of systemic juvenile idiopathic arthritis. Arthritis Rheumatol. 2014;66:2570–2579.
54. De Benedetti F, Brunner HI, Ruperto N, et al. Randomized trial of tocilizumab in systemic juvenile idiopathic arthritis. N Engl J Med. 2012;367:2385–2395.
55. Kim YJ, Koo BS, Kim YG, et al. Clinical features and prognosis in 82 patients with adult-onset Still’s disease. Clin Exp Rheumatol. 2014;32:28–33.
56. Giacomelli R, Gorla R, Trotta F, et al. Quality of life and unmet needs in patients with inflammatory arthropathies: results from the multicentre, observational RAPSODIA study. Rheumatology (Oxford). 2015;54:792–797.
57. Ursini F, D’Angelo S, Padula A, et al. Retrospective analysis of type 2 diabetes prevalence in a systemic sclerosis cohort from southern Italy: comment on “Reduced incidence of type 1 diabetes and type 2 diabetes in systemic sclerosis: A nationwide cohort study” by Tseng et al., Joint Bone Spine 2016;83:307-13. Joint Bone Spine. 2016;83:611–612.
58. Ursini F, Naty S, Mazzei V, et al. Kaposi’s sarcoma in a psoriatic arthritis patient treated with infliximab. Int Immunopharmacol. 2010;10:827–828.
59. Cipriani P, Berardicurti O, Masedu F, et al. Biologic therapies and infections in the daily practice of three Italian rheumatologic units: a prospective, observational study. Clin Rheumatol. 2017;36:251–260.
60. Carubbi F, Zugaro L, Cipriani P, et al. Safety and efficacy of intra-articular anti-tumor necrosis factor α agents compared to corticosteroids in a treat-to-target strategy in patients with inflammatory arthritis and monoarthritis flare. Int J Immunopathol Pharmacol. 2016;29:252–266.
61. Ursini F, Grembiale A, Naty S, et al. Serum complement C3 correlates with insulin resistance in never treated psoriatic arthritis patients. Clin Rheumatol. 2014;33:1759–1764.
62. Giacomelli R, Afeltra A, Alunno A, et al. International consensus: what else can we do to improve diagnosis and therapeutic strategies in patients affected by autoimmune rheumatic diseases (rheumatoid arthritis, spondyloarthritides, systemic sclerosis, systemic lupus erythematosus, antiphospholipid syndrome and Sjogren’s syndrome)?: the unmet needs and the clinical grey zone in autoimmune disease management. Autoimmun Rev. 2017;16:911–924.
63. Colafrancesco S, Priori R, Valesini G, et al. Response to interleukin-1 inhibitors in 140 Italian patients with adult-onset Still’s disease: a multicentre retrospective observational study. Front Pharmacol. 2017;8:369.